namilumab   Click here for help

GtoPdb Ligand ID: 10370

Synonyms: AMG203 [5] | MT203
Immunopharmacology Ligand
Compound class: Antibody
Comment: Namilumab (AMG203, MT203) is an IgG1κ anti-macrophage colony-stimulating factor (GM-CSF; CSF2) monoclonal antibody [2]. It is being developed by Micromet and Nycomed for the treatment of autoimmune and chronic inflammatory diseases.
Peptide sequences and structural information for this antibody are available from its IMGT/mAb-DB entry.
Immunopharmacology Comments
Initial preclinical efficacy utilising the anti-GM-CSF strategy in a rodent RA model was reported in 2007 [4]. First in human (Phase 1b) results using namilumab were published in 2017 [1]. Namilumab has since demonstrated clinical efficacy in RA patients who have an inadequate response to methotrexate or anti-tumour necrosis factor (TNF) biologic therapy, in a Phase 2 clinical proof-of-concept study [5].
Immunopharmacology Disease
Disease X-Refs Comment References
Psoriasis Disease Ontology: DOID:8893
Phase 2 evaluation of namilumab therapy in patients with plaque type psoriasis determined that GM-CSF blockade was not an amenable pathway for treatment of this condition. 3
Rheumatoid arthritis Disease Ontology: DOID:7148
OMIM: 180300
Phase 2 clinical candidate for RA: namilumab has demonstrated clinical efficacy in methotexate and anti-TNF therapy-resistant RA patients 5